Salix Pharmaceuticals Buys Santarus for $32 Per Share

Salix Pharmaceuticals will buy Santarus for $32 per share in a transaction expected to close in the first quarter of 2014.

The per share price values Santarus at $2.6 billion, a 39 percent premium over the company's 30-day trading average.

The acquisition will help Salix solidify its lead in the gastrointestinal market, and the companies' combined revenue would be approximately $1.3 billion.

More Articles on Gastroenterology:
72% of Adults Have Not Sought Physician Help for GI Pain
Physicians Endoscopy Receives Cost Management Performance Award
Dr. Glenn Madokoro Gives GI Patients Access to Information Technology

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast